拉米夫定联合抗乙肝特异性转移因子治疗慢性乙型肝炎临床疗效观察  

Clinical Efficiency of the Treating Chronic Hepatitis B with Lamivudine and HBV Special Transfer Factor

作　　者：刘茂生[1] 李红[1] 王国华[2] 

机构地区：[1]西安市华山中心医院,陕西西安710043 [2]第四军医大学,陕西西安710032

出　　处：《实用医技杂志》2005年第09B期2507-2508,共2页Journal of Practical Medical Techniques

摘　　要：目的:观察拉米夫定联合抗乙肝特异性转移因子治疗慢性乙型肝炎疗效。方法:58例慢性乙肝病人随机分成联合治疗组及拉米夫定组,联合治疗组用拉米夫定100 mg/d,口服,疗程12个月,抗乙肝特异性转移因子2 U肌肉注射,每2 d/次,疗程6个月;对照组用拉米夫定100 mg/d,口服,疗程12个月。结果:治疗后3个月、6个月、12个月复查HBeAg转阴率及抗HBe阳转率明显高于对照组(P<0.05)。结论:拉米夫定与抗乙肝特异性转移因子联合治疗慢性乙型肝炎有协同作用。Objective To observe the efficiency of lamividine combined with HBV special transfer factor treating chronic hepatitis B. Methods 58 chronic hepatitis B patients were randomly assigned to two groups. Patients in clmbimed treatment group were treated with lamivudine（100 mg/d ,orally,for 12 months）combined with HBV special transfer factor（2/time,once every other day,injection,for 6 months）. Results 3,6,12 months after they finished fheir treatment, the rate of HBeAg tuning negative and the rate of anti-HBeAg were significantly different in patients treated with different methods.Conclusions Treating chronic hepatits B with lamivudine and HBV special transfer factor had a coordinated effect.

关 键 词：拉米夫定 抗乙肝特异性转移因子 慢性乙型肝炎 治疗 

分 类 号：R512.62[医药卫生—内科学]